Tempest Therapeutics, Inc. announced that two abstracts have been accepted for poster presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting taking place April 14-19, 2023 in Orlando, FL. The presentations will highlight biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR? antagonist and preclinical data from TREX1 inhibitor, a tumor-selective STING pathway activator.